Malignant melanoma in the year 2000

Ca-A Cancer Journal for Clinicians

Volumn 50, Issue 4, 2000, Pages 209-213

  Burton, Robert C ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; SUNSCREEN;

ADOLESCENCE; AGE; AUSTRALIA; BLISTER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CHILDHOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; EDITORIAL; FEMALE; GENDER; HEALTH PROGRAM; HUMAN; LYMPH NODE DISSECTION; MALE; MELANOMA; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; SELF EXAMINATION; SKIN CANCER; SUN EXPOSURE; SUNBURN;

EID: 0033841783     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.50.4.209     Document Type: Editorial

References (32)

1. Malignant melanoma: Prevention, early detection, and treatment in the 21st century
2. Health System Costs of Cancer in Australia 1993-94
3. Aspects of screening for skin cancer
4. Cancer in Australia 1996: Incedence and Morality Data for 1996 and Selected Data for 1997 and 1998
5. How much melanoma is caused by sun exposure?
6. Sunlight and cancer
7. Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994
8. Cutaneous Melanoma in NSW in 1983 to 1995
9. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: Are primary prevention programs starting to have an effect?
10. Clinical Practice Guidelines for the Management of Cutaneous Melanoma
11. Some environmental and bodily characteristics of melanoma patients. A case-control study
12. An inquiry into the epidemiology of melanoma
13. Malignant melanoma: Aetiological importance of individual pigmentation and sun exposure
14. A case-control study of malignant melanoma of the trunk among white males in upstate New York
15. Is the use of sunscreens a risk factor for malignant melanoma?
16. Melanoma and the use of sunscreens: An EORTC case-control study in Germany, Belgium and France. The EORTC Melanoma Cooperative Group
17. Phenotypic markers, sunlight-related factors and sunscreen use in patients with cutaneous melanoma: An Austrian case-control study
18. Sunscreen use and malignant melanoma
19. Changes in sun-related attitudes and behaviours, and reduced sunburn prevalence in a population at high risk of melanoma
20. Analysis of public education and the implications with regard to non-progressive thin melanomas
21. General practitioner screening for melanoma: Sensitivity, specificity and effect of training
22. Recent incidence trends imply a non-metastasizing form of invasive melanoma
23. Non-metastasizing melanoma?
24. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
25. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
26. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma
27. Preliminary analysis of the E1690/S9111/C9190 intergroup postoperative adjuvant trial of high- and low-dose IFNa2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma
28. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma
29. Evaluation of efficacy of adjuvant rIFNa2a in melanoma patients with regional node metastases
30. The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: Prognosis versus efficacy, toxicity and costs
31. Eighty years of immunotherapy: A review of immunological methods used for the treatment of human cancer